Exclusive: A new startup called Junevity has raised $10M to identify renegade proteins (transcription factors) linked to aging and disease and silence them with long-lasting siRNA therapies.

Junevity emerges with $10M to ‘reset’ cells to a healthy state. Startup aims to restore key transcription factors with siRNA therapeutics to reverse cellular dysfunction and combat age-related diseases.

Junevity debuts with $10M to turn back the clock on cellular damage and has just the right technology to do so.

Business Wire: Junevity Raises $10M to Develop Cell Reset Therapeutics for Longevity. Based on pioneering research for resetting cell health by Dr. Janine Sengstack of UCSF.

Dr. Janine Sengstack speaks on the Stanford School of Medicine and SIC panel at JP Morgan Healthcare 2025 in San Francisco, CA on raising VC funding in biotech.

Dr. John Hoekman presents a poster at the 2024 World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Hollywood, CA on a novel siRNA insulin sensitizer.

Dr. Janine Sengstack presents at Longevity Summit 2024 at the Buck Institute for Aging Research.

PNAS publishes co-founder Rob Cahill’s UCSF research on creating biological maps of the mouse brain using spatial transcriptomics and machine learning, in collaboration with the Allen Institute for Brain Science.

Dr. Janine Sengstack shares her scientific journey and inspiration with The Alliance for Longevity’s Dr. Brenda Eap.

Dr. Janine Sengstack presents at The Aesthetic and Anti-Aging Medicine World Congress 2024 in Monaco, as guest of Allergan Aesthetics, an Abbvie Company.

Dr. Janine Sengstack presents at the 2024 Rejuvenation Startup Summit in Berlin.